A randomized , placebo-controlled, investigator sponsored clinical trial to evaluate Osanetant to reduce the frequency and severity of acute stress disorder and post-traumatic stress disorder (PTSD)
Latest Information Update: 04 Apr 2023
At a glance
- Drugs Osanetant (Primary)
- Indications Acute traumatic stress disorders; Post-traumatic stress disorders
- Focus Therapeutic Use
- Acronyms OASIS
Most Recent Events
- 16 Mar 2023 According to an Acer Therapeutics media release, ACER-801 did not achieve statistical significance when evaluating its ability to decrease frequency or severity of hot flashes in postmenopausal women. As a result, company is pausing ACER-801 program until company has conducted a thorough review of the full data set.
- 16 Mar 2023 Status changed from planning to suspended, according to an Acer Therapeutics media release.
- 12 Oct 2022 New trial record